title: [Hemolitic uremic syndrome with hypertransaminasemia following treatment by interferon for chronic myeloid leukemia].
authors.forename: N
authors.initials: N
authors.lastname: Denizon
authors.forename: J J
authors.initials: JJ
authors.lastname: Beraud
authors.forename: G
authors.initials: G
authors.lastname: Mourad
authors.forename: P
authors.initials: P
authors.lastname: Blanc
authors.forename: J P
authors.initials: JP
authors.lastname: Bureau
authors.forename: M
authors.initials: M
authors.lastname: Navarro
authors.forename: T
authors.initials: T
authors.lastname: Lavabre-Bertrand
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood*; D006463:Hemolytic-Uremic Syndrome / Q000201:enzymology / Q000209:etiology*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male
chemical_list: D016898:Interferon-alpha; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase